Immune Profile and Complication Risk in Type 2 Diabetes (IMPACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00674271|
Recruitment Status : Unknown
Verified November 2011 by University of Aarhus.
Recruitment status was: Active, not recruiting
First Posted : May 7, 2008
Last Update Posted : November 4, 2011
The aim of this study is to investigate the relation between individual differences in pattern recognition molecules (PRM's) in the innate immune system and the prevalence and development of vascular complications in patients with type 2 diabetes.
This is based on the hypothesis that pattern recognition molecules (PRM's) in the innate immune system contributes to a chronic low grade inflammation in diabetic patients. Variation in PRM's - at the genome, proteome as well as the functional level - are therefore associated with the degree of chronic low grade inflammation, and probably also with the prevalence of vascular complications.
|Condition or disease|
|Diabetes Mellitus, Type 2|
Aim: The primary aims of the project are:
- By use of advanced magnetic resonance imaging to characterize the prevalence of atherosclerosis in the carotid arteries in patients with newly diagnosed type 2 diabetes.
- To investigate if individual differences in the innate immune system contributes to the prevalence and development of cardiovascular disease in patients with type 2 diabetes.
- To prospectively observe the cardiovascular morbidity and mortality in a cohort of patients with type 2 diabetes seen in the light of the obtained baseline characteristics.
Background: Type 2 diabetes is a very common disease in the western world. Patients with type 2 diabetes are at risk of a number of complications, including macroangiopathy which involves an accelerated atherosclerosis, that causes most of the increased mortality and morbidity in type 2 diabetics. Mounting evidence suggests that development of vascular complications is associated to a chronic low grad inflammation in type 2 diabetes. Individual differences in the innate immune system might contribute to this chronic low grade inflammation as it has become apparent that in some situations - as after tissue ischemia or in diabetes - a change in the body's own cell glycosylations occurs, which leads to increased affinity of PRM's. This study will focus primarily on two families of PRM's: Collectins and Toll-like receptors.
Methods: The study consists of a prospective observational cohort study of 100 newly diagnosed type 2 diabetic patients with continuous 2-year clinical follow-up and a register-based follow-up of morbidity and mortality study after 5 and 10 years. Furthermore 100 healthy control subjects will be included. Baseline data will represent a independent cross-sectional study of the relationship between the innate immune system, glycemic control and the presence of atherosclerosis in the carotid arteries in newly diagnosed type 2 diabetic patients.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Immune Profile and Complications Risk in Type 2 Diabetes|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||March 2011|
|Estimated Study Completion Date :||May 2018|
100 patients with newly diagnosed (<5 years since diagnosis) type 2 diabetes referred from general practitioners to Medical Department M, Aarhus University Hospital, Denmark.
100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects matched for age and gender
- Plaque burden in carotid arteries [ Time Frame: Individual ]
- Serum levels of pattern recognition molecules [ Time Frame: Individual ]
- Genotyping genes for pattern recognition molecules [ Time Frame: Individual ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00674271
|Medical Department M, Aarhus University Hospital|
|Aarhus C, Denmark, 8000|
|Principal Investigator:||Jens S Christiansen, Prof., MD||Medical Department M, Aarhus University Hospital, Denmark|